A new study is going to take place in the USA to collect the perspectives of adolescents and young adults with achondroplasia about medicine options and choices for achondroplasia.

The pharmaceutical company Pfizer has recently decided to discontinue development of the drug Recifercept for the treatment of achondroplasia. 

Last month Ascendis Pharma revealed results on the Phase 2 ACcomplisH Trial in children with achondroplasia aged 2-10, showing TransCon CNP's potential to meet patient and caregiver needs for a safe, effective, tolerable, and convenient treatment for this condition.

A research team at Baylor College of Medicine and Texas Children’s Hospital in the United States is conducting a research study that you may be eligible for!

Inês Alves, ANDO Portugal founder, is leading a doctoral research program by Évora University on "Physical, Biomechanical, Nutritional and Psychological Characterization of adults with Achondroplasia, associated to physical activity, exercise and sports". This is an academic study supported by ANDO Portugal - National Organization for Skeletal Dysplasia.

Ahead of the upcoming workshop on 27th October 2022, 16:30 CET, Clinical Management Challenges in Infants and Young Children with Achondroplasia, EAF is undertaking two surveys to establish the challenges of managing achondroplasia in these age groups: one for parents of children with achondroplasia and one for clinicians.